all report title image

GLOBAL DIABETIC LANCING DEVICE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Diabetic Lancing Device Market, By Product Type (Standard Lancets, Safety Lancets, Flake Lancets, and Others), By Gauge Size (17/18g, 21g, 23g, 25g, and Others), By End User (Hospitals, Clinics, Diagnostic Centers, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published In : Apr 2024
  • Code : CMI6926
  • Pages :167
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Global Diabetic Lancing Device Market Size and Trends

Global diabetic lancing device market is estimated to be valued at USD 928.2 Mn in 2024 and is expected to reach USD 1,786.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031.

Global Diabetic Lancing Device Market Key Factors

Discover market dynamics shaping the industry: Request sample copy

The diabetic lancing device market is expected to witness considerable growth over the forecast period. The growing prevalence of diabetes worldwide is the key factor driving the market growth. As per the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide, and the number is projected to rise to 783 million by 2045. Moreover, increasing awareness about diabetes management and regular glucose monitoring is also expected to boost demand for lancing devices in the coming years. With technological advancements, various players are focusing on developing innovative products with improved features like adjustable depth settings and painless actuation mechanisms, which is further augmenting the market expansion. However, the availability of alternative painless methods for glucose testing and high costs associated with advanced devices may hamper the market growth to some extent over the forecast years.

Rising prevalence of diabetes

The global prevalence of diabetes has been steadily increasing over the past few decades. According to the World Health Organization, the global prevalence of diabetes among adults over 18 years of age has nearly doubled. The International Diabetes Federation estimated that by 2045, approximately 629 million people, which is around 1 in 10 adults, will be living with diabetes globally. This rising burden of diabetes can primarily be attributed to the increasing trends of obesity, physical inactivity, and unhealthy diet across both developed and developing nations. As diabetes leads to significant health complications if not managed properly, with regular monitoring of blood glucose levels an absolute necessity. The increasing patient base is likely to directly contribute to the growing demand for diabetic testing and lancing devices.

Market Concentration and Competitive Landscape

Global Diabetic Lancing Device Market Concentration By Players

Get actionable strategies to beat competition: Request sample copy

Advancements in design and features

Continuous efforts towards innovation and advancement by leading manufacturers have transformed these devices to become more convenient, effective and painless. Some of the key developments that have enhanced user experience include adjustable depth settings to control puncture depth, softer needle tips for reduced pain, improved ergonomics for one-handed operation, automatic release of needles for safe disposal and data connectivity features. In recent years, manufacturers have also started focusing on miniaturization and greater portability to encourage compliance. These ongoing enhancements are lowering the barriers for regular self-monitoring and helping generate higher acceptance amongst patients. With manufacturers expected to further refine existing technologies and develop smart solutions integrated with digital health platforms, demand is likely to stay robust as users continuously upgrade to new devices offering enhanced features and experience. 

Global Diabetic Lancing Device Market Key Takeaways From Lead Analyst

To learn more about this report, Request sample copy

Market Challenges – Availability of alternative techniques for blood glucose testing

One of the key challenges faced by the global diabetic lancing device market is the availability of alternative techniques for blood glucose testing that do not require finger pricks, such as continuous glucose monitoring systems. Additionally, the pain associated with traditional lancing devices can reduce compliance for regular self-monitoring of blood glucose levels among patients. This acts as a major hindrance to the growth of the global diabetic lancing device market.

Market Opportunities – Development of User-friendly and Pain-free Lancing Devices

The development of lancing devices that are easier to use and cause less pain for patients could unlock significant growth opportunities in the global diabetic lancing device market. Currently, finger pricks for blood glucose monitoring are often cited as one of the most unpleasant parts of diabetes management. This barrier to regular self-testing negatively impacts treatment outcomes and quality of life for many patients. Addressing this pain point with new user-friendly designs could dramatically improve adherence to testing protocols.

Global Diabetic Lancing Device Market By Product Type

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights, By Product Type: Convenience and patient safety drive demand for standard lancets

The Product Type segment is sub-segmented into standard lancets, safety lancets, flake lancets, others. Standard lancets segment is estimated to hold 61.4% of the market share in 2024 owing to their convenient design and focus on patient safety. Standard lancets are simple to use for self-lancing and require minimal training. The widespread use of standard lancets in diabetes care, due to the increasing prevalence of diabetes, and the growing awareness of diabetes' impact on public health. The market is expected to continue growing due to technological advancements, favorable reimbursement policies, increasing healthcare expenditure, and the growing adoption of point-of-care testing.

Insights, By Gauge Size: Precise gauges optimize sampling for testing accuracy

Gauge size segment is sub-segmented into 17/18g, 21g, 23g, 25g, and Others. The 17/18g segment is estimated to hold 37.4% of the market share in 2024, as it offers an ideal balance between painless lancing and sufficient blood volume for testing. Narrower gauges like 21g and 23g result in less puncture pain but may require multiple pricks to obtain the minimum blood volume for accurate readings. Wider needles increase risks of bruising and discomfort. The 17/18g gauge has been optimized through extensive clinical use to provide reliable single-stick sampling with average pain levels. This consistency suits self-testing use cases at home or in doctor facilities. It ensures testing validity on the first attempt without complications, saving time. Precise gauging thus streamlines the monitoring process for convenient diabetes management while still placing patient experience as a high priority.

Insights, By End User: Hospitals lead adoption driven by large caseloads and regulatory protocols

End User segment is sub-segmented into hospitals, clinics, diagnostic centers, and others (home care settings, etc.). Hospitals segment is estimated to hold 34.7% of the market share in 2024, due to large patient caseloads and compliance requirements. Diabetic complications often necessitate in-patient care and intensive monitoring managed by a hospital team. Centralization of resources in hospitals also facilitates management of medical waste and sharps as per biomedical norms to maintain safety. Adoption is further augmented considering hospitals serve high-risk groups such as pregnant diabetics requiring additional caution.

Regional Insights

Global Diabetic Lancing Device Market Regional Insights

To learn more about this report, Request sample copy

North America remains the dominant region in the global diabetic lancing device market and is estimated to hold 34.6% of the market share in 2024 owing to the large diabetic population in the region. The U.S. accounts for the major share primarily due to the high healthcare expenditure and presence of many leading device manufacturers. Moreover, the reimbursement coverage for diabetes management devices in the country supports the use of lancing devices thereby augmenting market growth. Manufacturers find North America as an attractive location for distribution and export of diabetic lancing devices to other regions globally due to the strategically advantaged distribution channels and existing customer networks. These further aids their dominance in the overall market. However, pricing pressure from generic products may challenge premium product sales in the coming years.

The Asia Pacific region has been witnessing impressive growth and is emerging as the fastest growing regional market for diabetic lancing devices. The growing prevalence of diabetes, increasing healthcare expenditure, large patient pool, and rising awareness about diabetes management are some of the major factors responsible for the robust growth. Many domestic players are entering the market in countries like China, India and Japan due to low manufacturing costs and presence of raw material suppliers. These manufacturers export affordable products to other Asian as well as African countries. However, lack of stringent regulatory policies and quality oversight poses risks regarding device efficacy and safety in some Asian nations.

Market Report Scope

Global Diabetic Lancing Device Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 928.2 Mn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 9.8% 2031 Value Projection: US$ 1,786.6 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type: Standard Lancets, Safety Lancets, Flake Lancets, and Others
  • By Gauge Size: 17/18g, 21g, 23g, 25g, and Others
  • By End User: Hospitals, Clinics, Diagnostic Centers, and Others (Home Care Settings, etc.) 
Companies covered:

Genteel LLC., Abbott, BD, Braun SE, F. Hoffmann-La Roche Ltd, Greiner Bio-One International GmbH, Eli Lilly and Company, Allison Medical, Inc., Diabetyk24 z o.o., i-SENS, Inc., Nipro Corporation, Medisave UK Ltd, Home Health Ltd, Medtronic, ARKRAY, Inc., Owen Mumford, and LifeScan IP Holdings, LLC.

Growth Drivers:
  • Rising Prevalence of Diabetes
  • Advancements in Design and Features
Restraints & Challenges:
  • Availability of Alternative Techniques for Blood Glucose Testing
  • Risks and Complications Associated with Inaccurate Lancing

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Diabetic Lancing Device Industry News

  • In August 2023, Hoffmann-La Roche Ltd, a pharmaceutical company, announced that it had launched Accu-Chek Pico, a handy and fully disposable lancet device for blood glucose monitoring to enhance diabetes care for older people living with diabetes nationwide. Accu-Chek Pico will be available in medical institutions such as hospitals and retail pharmacies across Japan.

*Definition: Diabetes lancing devices are hand-held instruments that contain a thin needle which is used to prick the skin, typically on the fingertips, to draw a small blood sample for testing. They automate the finger-pricking process, reducing pain for the user compared to manual lancets. The devices produce a consistently shallow penetration to obtain an adequate blood sample.

Market Segmentation

  • Product Type Insights (Revenue, USD Mn, 2019 - 2031)
    • Standard Lancets
    • Safety Lancets
    • Flake Lancets
    • Others
  •  Gauge Size Insights (Revenue, USD Mn, 2019 - 2031)
    • 17/18g
    • 21g
    • 23g
    • 25g
    • Others
  •  End User Insights (Revenue, USD Mn, 2019 - 2031)
    • Hospitals
    • Clinics
    • Diagnostic Centers
    • Others (Home Care Settings, etc.)
  • Regional Insights (Revenue, USD Mn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Genteel LLC. 
    • Abbott 
    • BD
    • Braun SE
    • F. Hoffmann-La Roche Ltd
    • Greiner Bio-One International GmbH
    • Eli Lilly and Company
    • Allison Medical, Inc.
    • Diabetyk24 z o.o. 
    • i-SENS, Inc.
    • Nipro Corporation
    • Medisave UK Ltd
    • Home Health Ltd
    • Medtronic
    • ARKRAY, Inc.
    • Owen Mumford
    • LifeScan IP Holdings, LLC.

Share

About Author

Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Global Diabetic Lancing Device Market size is estimated to be valued at USD 928.2 million in 2024 and is expected to reach USD 1,786.6 million in 2031.

The CAGR of the diabetic lancing device market is projected to be 9.8% from 2024 to 2031.

Rising prevalence of diabetes and advancements in design and features are the major factors driving the growth of the diabetic lancing device market.

Availability of alternative techniques for blood glucose testing and risks and complications associated with inaccurate lancing are the major factor hampering the growth of the diabetic lancing device market.

In terms of Product Type, Standard Lancets is estimated to dominate the market revenue share in 2024.

Genteel LLC., Abbott, BD, Braun SE, F. Hoffmann-La Roche Ltd, Greiner Bio-One International GmbH, Eli Lilly and Company, Allison Medical, Inc., Diabetyk24 z o.o., i-SENS, Inc., Nipro Corporation, Medisave UK Ltd, Home Health Ltd, Medtronic, ARKRAY, Inc., Owen Mumford, and LifeScan IP Holdings, LLC. are the major players.

North America is expected to lead the diabetic lancing device market.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Select a License Type





Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.